AR019724A2 - PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS - Google Patents

PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS

Info

Publication number
AR019724A2
AR019724A2 ARP990103110A ARP990103110A AR019724A2 AR 019724 A2 AR019724 A2 AR 019724A2 AR P990103110 A ARP990103110 A AR P990103110A AR P990103110 A ARP990103110 A AR P990103110A AR 019724 A2 AR019724 A2 AR 019724A2
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
composition useful
associated conditions
mellitus diabetes
Prior art date
Application number
ARP990103110A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR019724A2 publication Critical patent/AR019724A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Una composicion farmacéutica que comprende un sensibilizador a insulina, un secretagogo de insulina, un agente antihiperglucémico inhibidor dealfa-glucosidasa, y un vehículo farmacéuticamente aceptable, util para el tratamiento de la diabetes mellitus y las condiciones asociadas con la diabetesmellitus en un mamífero.A pharmaceutical composition comprising an insulin sensitizer, an insulin secretagogue, an anti-hyperglycemic agent anti-glucosidase inhibitor, and a pharmaceutically acceptable carrier, useful for the treatment of diabetes mellitus and the conditions associated with diabetesmellitus in a mammal.

ARP990103110A 1997-07-18 1999-06-28 PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS AR019724A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
AR019724A2 true AR019724A2 (en) 2002-03-13

Family

ID=10816170

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980103482A AR016350A1 (en) 1997-07-18 1998-07-16 USE OF AN INSULIN SENSITIZER, AN INSULIN SECRETAGOG AND AN ALFA-GLUCOSIDASE INHIBITING ANTI-HERITAGE AGENT TO PREPARE MEDICATIONS
ARP990103110A AR019724A2 (en) 1997-07-18 1999-06-28 PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980103482A AR016350A1 (en) 1997-07-18 1998-07-16 USE OF AN INSULIN SENSITIZER, AN INSULIN SECRETAGOG AND AN ALFA-GLUCOSIDASE INHIBITING ANTI-HERITAGE AGENT TO PREPARE MEDICATIONS

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230D0 (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2291210T3 (en) * 1999-06-21 2008-03-01 Eli Lilly And Company SYNERGISTIC USE OF THIAZOLIDINDIONAS WITH PEPTIDO-1 TYPE GLUCAGONA AND ITS AGONISTS TO TREAT NON-INSULIN-DEPENDENT DIABETES.
BRPI0107715B8 (en) * 2000-01-21 2021-05-25 Novartis Ag pharmaceutical product comprising an inhibitor of dipeptidyl peptidase-iv and metformin, as well as uses of said pharmaceutical product and inhibitor of dipeptidyl peptidase-iv
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
JP4633329B2 (en) 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
PL338140A1 (en) 2000-09-25
SK612000A3 (en) 2000-07-11
ZA986364B (en) 2000-01-17
CN1263467A (en) 2000-08-16
NO20000230L (en) 2000-01-17
AR016350A1 (en) 2001-07-04
GB9715298D0 (en) 1997-09-24
WO1999003478A1 (en) 1999-01-28
UY25101A1 (en) 2000-12-29
HUP0003626A3 (en) 2001-12-28
BG104062A (en) 2000-11-30
DZ2563A1 (en) 2003-02-15
TR200000133T2 (en) 2000-09-21
CO4940489A1 (en) 2000-07-24
ID23804A (en) 2000-05-11
EP1001784A1 (en) 2000-05-24
AU8449098A (en) 1999-02-10
MA24608A1 (en) 1999-04-01
NO20000230D0 (en) 2000-01-17
IL133907A0 (en) 2001-04-30
PE99499A1 (en) 1999-12-18
KR20010021952A (en) 2001-03-15
BR9810292A (en) 2000-09-19
CA2297133A1 (en) 1999-01-28
OA11312A (en) 2003-10-24
JP2001510160A (en) 2001-07-31
HUP0003626A2 (en) 2001-05-28
AP2000001735A0 (en) 2000-01-16
EA200000140A1 (en) 2000-06-26

Similar Documents

Publication Publication Date Title
AR012998A1 (en) USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SENSITIZER AND SUCH AGENT.
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CL2009001899A1 (en) Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
KR870005637A (en) Drug depot
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
AR019724A2 (en) PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS
UY25798A1 (en) PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE INCLUDING A THIAZOLIDINADIONIC INSULIN SENSITIZER.
AR046210A1 (en) SOLID PREPARATION
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
CO4940454A1 (en) NEW METHOD OF TREATMENT
UY25103A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS
AR008025A1 (en) PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA AND AN INSULIN SECRETOGOGUE
AR013352A1 (en) USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DIABETES MELLITUS AND CONDITIONS ASSOCIATED WITH IT AND A PHARMACEUTICAL COMPOSITION.
TR200101336T2 (en) Combinations with a beta-agonist and another antidiabetic agent
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP993215A (en) NEW COMPOSITION AND USE
ECSP982541A (en) NEW METHOD OF TREATMENT II
ECSP982591A (en) NEW METHOD OF TREATMENT IV
ECSP982535A (en) NEW TREATMENT METHOD (I)
UY25801A1 (en) PROCEDURE FOR PREPARING COMPOSITIONS FOR THE TREATMENT OF DIABETES.
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982542A (en) NEW METHOD OF TREATMENT III
ECSP982592A (en) NEW METHOD OF TREATMENT V
ECSP993216A (en) NEW COMPOSITION AND USE II
TR200000957T2 (en) The use of thiazolidinedione in the treatment of hyperglycemia